Dolat Capital Market's research report on Dabur India
Dabur’s Q2FY21 results exceed our estimate. Domestic FMCG volumes increased by 16.8% YoY. Growth in the domestic market was driven by health care (+49.3%) and HPC (9.1%) business. Healthcare contribution grew from 32% in Q2FY20 to 40% in Q2FY21 led by 2x growth in Chyawanprash and double digit growth in Honey- indicates change in consumer preferences. We believe that the healthcare category would continue to grow faster post Covid with new launches.
Outlook
We have upward revised our FY21E and FY23E EPS estimates at Rs 9.5 (+13%) and Rs 9.8 (+0.8%) and introduced FY23E EPS estimates at Rs 10.8. We value the stock at 48x FY23E EPS to arrive at a TP of Rs 520. Considering rich valuations, we maintain Reduce; buy on dips.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.